drugset / Trial / NCT03912857
Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.This study was a one-arm, single-center, open clinical study. A total of 50 patients were enrolled in the study.
Timeline
- Start
- 2018-12-01
- Primary completion
- 2019-12-01
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | Rivoceranib | Small molecule | 375 mg | — |